- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium Inhalation Solution, Placebo
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 983 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Pismo Beach, California • San Diego, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 33,591
matching trials from the live ClinicalTrials.gov search.
- Conditions
- High Altitude Pulmonary Hypertension
- Interventions
- Aminophylline, Ambrisentan, Aminophylline plus ambrisentan
- Drug
- Lead sponsor
- Thies Schroeder
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Depression
- Interventions
- Armodafinil, Placebo
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Garden Grove, California + 36 more
- Conditions
- Childhood Absence Epilepsy, Juvenile Absence Epilepsy
- Interventions
- Brivaracetam Film-coated tablet, Brivaracetam oral solution
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • New Brunswick, New Jersey • Winston-Salem, North Carolina
- Conditions
- Influenza
- Interventions
- Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, Placebo
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 11,404 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 17
- States / cities
- Denver, Colorado • Pembroke Pines, Florida • South Miami, Florida + 13 more
- Conditions
- Overactive Bladder (OAB), Urinary Urgency, Urinary Urge Incontinence (UUI), Nocturia, Urinary Frequency
- Interventions
- RiSolve App, AUGS Patient Handouts
- Device · Behavioral
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 22 Years and older · Female only
- Enrollment
- 596 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Duarte, California • Irvine, California • Orange, California + 9 more
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
- Interventions
- SB-007
- Genetic
- Lead sponsor
- Splice Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Miami, Florida • Boston, Massachusetts + 2 more
- Conditions
- Asthma
- Interventions
- GP MDI, BFF MDI, Placebo MDI
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Bakersfield, California • Lancaster, California • Long Beach, California + 12 more
- Conditions
- Glaucoma, Angle-Closure, Ocular Hypertension
- Interventions
- Travoprost (0.004%), Latanoprost (0.005%)
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Lupus
- Interventions
- MEDI-545
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 19
- States / cities
- Anniston, Alabama • Los Angeles, California • Clearwater, Florida + 14 more
- Conditions
- Healthy Volunteers
- Interventions
- GEH200520 Injection and GEH200521 (18F) Injection, Static - PET/CT scan
- Drug · Diagnostic Test
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hyperemia
- Interventions
- Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Infraorbital Hollows
- Interventions
- Restylane-L®
- Device
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 16
- States / cities
- Encino, California • Los Angeles, California • Redondo Beach, California + 12 more
- Conditions
- Critical Limb Ischemia, Arterial Occlusive Disease, Vascular Diseases
- Interventions
- autologous CD133+ cells
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance
- Interventions
- Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- San Jose, California • San Leandro, California • Santa Monica, California + 2 more
- Conditions
- Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
- Interventions
- RAP-219
- Drug
- Lead sponsor
- Rapport Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Boise, Idaho • Rochester, Minnesota • New York, New York + 4 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444, tiotropium bromide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 846 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • San Diego, California • DeLand, Florida + 16 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Andecaliximab, Placebo to match Andecaliximab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 5
- States / cities
- Miami, Florida • Orlando, Florida • Buffalo, New York + 1 more
- Conditions
- Tourette's Disorder
- Interventions
- vigabatrin
- Drug
- Lead sponsor
- Barbara J. Coffey
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- Interventions
- frexalimab, brivekimig, rilzabrutinib, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 15 more
- Conditions
- RSV Infection
- Interventions
- RSV 6120/∆NS2/1030s, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- SAR445088 (IV), SAR445088 (SC)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Orange, California • Fairway, Kansas + 2 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,037 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 49
- States / cities
- Alexander City, Alabama • Banning, California • Sylmar, California + 46 more